Ocgn stock

Ocugen (OCGN) Stock Down as FDA Puts Hold on Covaxin Study Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients...

Buy Ocugen, Inc. Stock

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. All Rights Reserved. self-directed individual brokerage accounts that trade U. listed securities electronically. Other fees may apply. See our for more information. Open to the Public Investing, Inc does not recommend any securities. All investments involve risk and ocgn stock past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The above content is provided for general informational purposes only. It is not intended to constitute investment advice or any other... Ocugen, Inc. (OCGN) Stock Price, News, Quote, Chart & Historical Prices

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates i